MODULATION THERAPEUTICS, INC.

Morgantown, WV · Biotech · Private

MTI-301, an oral small-molecule SCD1 inhibitor for treating non-alcoholic fatty liver disease and NASH

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · modulationtherapeutics.com

Sector: Biotech
Headquarters: Morgantown, WV
Total capital: $13.4M

Federal grants: $11.1M; 20 awards · 2015–2025; Rank in peer group#45 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $2.3M; 2 awards · Health and Human S; Rank in Biotech#131 of 4373
Granted patents: 2; 13 pending · first 2022; Rank in peer group#142 of 514

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase II · Modulation of cancer induced immune suppression via inhibition of SCD1$218K
Aug 2024Federal grantHealth and Human S · Phase II · Modulation of cancer induced immune suppression via inhibition of SCD1$670K
Aug 2023Federal grantHealth and Human S · Phase II · Modulation of cancer induced immune suppression via inhibition of SCD1$1.3M
May 2023Federal grantHealth and Human S · Phase I · MTI-301 a SCD1 inhibitor for the treatment of NASH$345K
Sep 2022Federal grantHealth and Human S · Phase II · Modulation of cancer induced immune suppression via inhibition of SCD1$400K
Jul 2020Federal grantHealth and Human S · Phase II · Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma$213K
Aug 2019Federal grantHealth and Human S · Phase II · Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$764K

Show 15 earlier federal awards

Aug 2019Federal grantHealth and Human S · Phase II · Novel SCD1 inhibitors for treatment of cancer$1.2M
Jul 2019Federal grantHealth and Human S · Phase II · Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$4K
Feb 2019Federal grantHealth and Human S · Phase I · Development of mitoNEET agonists for the treatment of stroke$259K
Sep 2018Federal grantHealth and Human S · Phase I · Development of an a MC1R selective companion diagnostic imaging probe$248K
Sep 2018Federal grantHealth and Human S · Phase II · Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$1.2M
Sep 2018Federal grantHealth and Human S · Phase II · Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma$2.1M
Aug 2018Federal grantHealth and Human S · Phase II · Novel SCD1 inhibitors for treatment of cancer$763K
May 2018Federal grantHealth and Human S · Phase II · Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$50K
Sep 2017Federal grantHealth and Human S · Phase II · Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$242K
Sep 2017Federal contractHealth and Human S · Igf::ot::igf "targeted AC-225-RADIOPHARMACEUTICAL For Metastatic Uveal Melanoma"period Of Performance: 9/18/2017 - 9/17/2019$2M
Aug 2017Federal grantHealth and Human S · Phase I · Osteopontin targeted therapy for primary CNS lymphoma$284K
Aug 2017Federal grantHealth and Human S · Phase I · Osteopontin-targeted therapy for primary CNS lymphoma$284K
Mar 2016Federal grantHealth and Human S · Phase I · Novel SCD1 inhibitors for treatment of cancer$279K
Sep 2015Federal contractHealth and Human S · Igf::ot::igf SBIR Topic 339$299K
Jul 2015Federal grantHealth and Human S · Phase I · Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.$245K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#45 · top 9%
Granted patents#142 · top 28%
Linked publications#23 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 15

Dec 18, 2025PendingSCD1 Inhibitors For Treating Liver DiseaseUSPTOApplication 18877159
May 1, 2025PendingCyclic Peptide Compounds And Methods Of Use ThereofUSPTOApplication 18763815
Feb 27, 2025PendingTargeting ERO1 Alpha With Aurone DerivativesUSPTOApplication 18720324

Show all 15 patent records

SCD1 Inhibitors For Treating Liver DiseaseDec 18, 2025 · Application 18877159Pending
Cyclic Peptide Compounds And Methods Of Use ThereofMay 1, 2025 · Application 18763815Pending
Targeting ERO1 Alpha With Aurone DerivativesFeb 27, 2025 · Application 18720324Pending
Cyclic Peptide Compounds And Methods Of Use ThereofAug 13, 2024 · US 12,060,438Granted
Radiotherapeutic And Companion Imaging Agents To Target MC1RAug 9, 2022 · US 11,406,723Granted
SCD1 Inhibitors For Treating Liver DiseaseApplication 63356419Pending
Targeting ERO1 Alpha With Aurone DerivativesApplication 63267751Pending
Targeting ERO1 Alpha With Aurone DerivativesApplication 63265374Pending
Cyclic Peptide Compounds And Methods Of Use ThereofApplication PCTUS2019035652Pending
Radiotherapeutic And Companion Imaging AgentsApplication PCTUS2025041333Pending
Cyclic Peptide Compounds And Methods Of Use ThereofApplication 62680904Pending
Radiotherapeutic And Companion Imaging AgentsApplication 63680924Pending
SCD1 Inhibitors For Treating Hematolymphoid NeoplasmsApplication PCTUS2024037898Pending
SCD1 Inhibitors For Treating Hematolymphoid NeoplasmsApplication PCTUS2023027839Pending
SCD1 Inhibitors For Treating Liver DiseaseApplication PCTUS2023026371Pending

Recent research by its founders

Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia20257 cites
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma20251 cites
Data from The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma20250 cites

DIAGNOLOGIX, LLCSimilar federal contract value in Biotech · $2.4M in contracts
CHROMATAN INCSimilar federal contract value in Biotech · $2.3M in contracts
WILSON WOLF MANUFACTURING CORPORATIONSimilar federal contract value in Biotech · $2.3M in contracts
VIEWPOINT MOLECULAR TARGETING, INC.Similar federal contract value in Biotech · $2.2M in contracts
Vector Biomed Inc.Similar federal contract value in Biotech · $2.2M in contracts
MerusSimilar federal contract value in Biotech · $2.1M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.